Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol 'Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth 'Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone856-848-8698
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.67 million
Profitability
Miscellaneous
Employees13
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable
Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions
What is Akers Biosciences' stock symbol?
Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."
How were Akers Biosciences' earnings last quarter?
Akers Biosciences Inc (NASDAQ:AKER) issued its quarterly earnings data on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share for the quarter. The medical instruments supplier earned $0.56 million during the quarter. Akers Biosciences had a negative net margin of 359.43% and a negative return on equity of 136.53%. View Akers Biosciences' Earnings History.
When is Akers Biosciences' next earnings date?
Has Akers Biosciences been receiving favorable news coverage?
News stories about AKER stock have been trending neutral on Wednesday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akers Biosciences earned a daily sentiment score of 0.5 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Akers Biosciences.
Are investors shorting Akers Biosciences?
Akers Biosciences saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 619,500 shares, an increase of 16.8% from the September 30th total of 530,500 shares. Based on an average daily trading volume, of 178,500 shares, the days-to-cover ratio is presently 3.5 days. Currently, 5.0% of the company's stock are short sold. View Akers Biosciences' Current Options Chain.
Who are some of Akers Biosciences' key competitors?
Some companies that are related to Akers Biosciences include IDEXX Laboratories (IDXX), IPSEN S A/S (IPSEY), Immunomedics (IMMU), Neogen (NEOG), Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Lantheus (LNTH), Heska (HSKA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML) and ImmuCell (ICCC).
What other stocks do shareholders of Akers Biosciences own?
Who are Akers Biosciences' key executives?
Akers Biosciences' management team includes the folowing people:
- Mr. Howard R. Yeaton Jr., CPA, CEO & Interim CFO (Age 64)
- Mr. Douglas Carrara, Sr. VP of Global Marketing & Commercial Operations
- Ms. Pamela E. Hibler, VP of Sales & Distribution
- Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 63)
How do I buy shares of Akers Biosciences?
Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Akers Biosciences' stock price today?
One share of AKER stock can currently be purchased for approximately $3.12.
How big of a company is Akers Biosciences?
What is Akers Biosciences' official website?
How can I contact Akers Biosciences?
Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856-848-8698 or via email at [email protected]
MarketBeat Community Rating for Akers Biosciences (NASDAQ AKER)
MarketBeat's community ratings are surveys of what our community members think about Akers Biosciences and other stocks. Vote "Outperform" if you believe AKER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKER will underperform the S&P 500 over the long term. You may vote once every thirty days.
